liu.seSearch for publications in DiVA
Change search
ReferencesLink to record
Permanent link

Direct link
First Clinical Experience with the Magnetic Resonance Imaging Contrast Agent and Superoxide Dismutase Mimetic Mangafodipir as an Adjunct in Cancer Chemotherapy-A Translational Study
Linköping University, Department of Medical and Health Sciences. Linköping University, Faculty of Health Sciences.
County Hospital Ryhov, Sweden .
County Hospital Ryhov, Sweden .
Linköping University, Department of Medical and Health Sciences, Division of Drug Research. Linköping University, Faculty of Health Sciences.
Show others and affiliations
2012 (English)In: Translational Oncology, ISSN 1936-5233, Vol. 5, no 1, 32-38 p.Article in journal (Refereed) Published
Abstract [en]

Preclinical research suggests that the clinically approved magnetic resonance imaging contrast agent mangafodipir may protect against adverse events (AEs) caused by chemotherapy, without interfering negatively with the anticancer efficacy. The present translational study tested if pretreatment with mangafodipir lowers AEs during curative (adjuvant) FOLFOX6 chemotherapy in stage III colon cancer (Dukes C). The study was originally scheduled to include 20 patients, but because of the unforeseen withdrawal of mangafodipir from the market, the study had to be closed after 14 patients had been included. The withdrawal of mangafodipir was purely based on commercial considerations from the producer and not on any safety concerns. The patients were treated throughout the first 3 of 12 scheduled cycles. Patients were randomized to a 5-minute infusion of either mangafodipir or placebo (7 in each group). AEs were evaluated according to the National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events and the Sanofi-NCI criteria. The primary end points were neutropenia and neurosensory toxicity. There were four AEs of grade 3 (severe) and one AE of grade 4 (life threatening) in four patients in the placebo group, whereas there were none in the mangafodipir group (P andlt; .05). Of the grade 3 and 4 events, two were neutropenia and one was neurosensory toxicity. Furthermore, white blood cell count was statistically, significantly higher in the mangafodipir group than in the placebo group (P andlt; .01) after treatment with FOLFOX. This small feasibility study seems to confirm what has been demonstrated preclinically, namely, that pretreatment with mangafodipir lowers AEs during adjuvant 5-fluorouracil plus oxaliplatin-based chemotherapy in colon cancer patients.

Place, publisher, year, edition, pages
NEOPLASIA PRESS, 1150 W MEDICAL CENTER DR, MSRB III, RM 9303, ANN ARBOR, MI 48109-0648 USA , 2012. Vol. 5, no 1, 32-38 p.
National Category
Medical and Health Sciences
URN: urn:nbn:se:liu:diva-79112DOI: 10.1593/tlo.11277ISI: 000304817600005OAI: diva2:538242

Funding Agencies|Medical Research Council of Southeast Sweden|FORSS-85191|PledPharma AB||

Available from: 2012-06-29 Created: 2012-06-29 Last updated: 2014-09-11Bibliographically approved

Open Access in DiVA

fulltext(314 kB)107 downloads
File information
File name FULLTEXT01.pdfFile size 314 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Karlsson, Jan OlofJynge, PerAndersson, RolfFalkmer, Ursula G
By organisation
Department of Medical and Health SciencesFaculty of Health SciencesDivision of Drug ResearchPharmacology
In the same journal
Translational Oncology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 107 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 91 hits
ReferencesLink to record
Permanent link

Direct link